What science says about terpenes, how they shape cannabis effects with cannabinoids, and what this means for patients and consumers in DC, Maryland and Virginia.

NORML’s op-ed argues cannabis does not share the health risks of heroin, cigarettes, or alcohol and calls for removing it from Schedule I. Here’s what that stance means.

Psychedelic Science Review reports a rapid rise in psilocybin interest, with 100+ clinical trials since the early 2000s and recent studies signaling strong therapeutic potential.

HRSA logged 59 comments on training and outpatient delivery models for potential FDA‑approved psychedelic therapies. We unpack what’s being explored, plus why credentials, clinics, and costs matter.

A look at non‑drug “technodelics” like mirrored chambers, strobe light journeys, and full‑body pods—and what early research suggests about benefits, safety, and limits.